CoChat

In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies

Pandey, Kirti, Mifsud, Nicole A., Lim Kam Sian, Terry C.C., Ayala, Rochelle, Ternette, Nicola, Ramarathinam, Sri H., Purcell, Anthony W. · 2020 · Molecular Immunology
Cited by 26

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molimm.2020.04.008

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 60

  1. Abelin, 2017, Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction, Immunity, 46, 315, 10.1016/j.immuni.2017.02.007 · DOI · Paper page
  2. Almeida, 2009, CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens, Nucleic Acids Res., 37, D816, 10.1093/nar/gkn673 · DOI · Paper page
  3. Alvarez, 2018, Computational tools for the identification and interpretation of sequence motifs in Immunopeptidomes, Proteomics, 12, 1700252, 10.1002/pmic.201700252 · DOI
  4. Barouch, 1995, HLA-A2 subtypes are functionally distinct in peptide binding and presentation, J. Exp. Med., 182, 1847, 10.1084/jem.182.6.1847 · DOI
  5. Bassani-Sternberg, 2015, Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation, Mol. Cell Proteomics, 14, 658, 10.1074/mcp.M114.042812 · DOI · Paper page
  6. Bassani-Sternberg, 2017, Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity, PLoS Comput Biol, 13, e1005725, 10.1371/journal.pcbi.1005725 · DOI · Paper page
  7. Battle, 2013, Molecular characterisation of the monocytic cell line THP-1 demonstrates a discrepancy with the documented HLA type, Int. J. Cancer, 132, 246, 10.1002/ijc.27661 · doi:10.1002/ijc.27661
  8. Blum, 2013, Pathways Antigen Processing, 31, 443
  9. Brodsky, 1982, Monomorphic anti-HLA-A,B,C monoclonal antibodies detecting molecular subunits and combinatorial determinants, J. Immunol., 128, 129, 10.4049/jimmunol.128.1.129 · DOI · Paper page
  10. Caron, 2011, The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation, Mol. Syst. Biol., 7, 533, 10.1038/msb.2011.68 · DOI · Paper page
  11. Caron, 2015, Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry, Mol. Cell Proteomics, 14, 3105, 10.1074/mcp.O115.052431 · DOI · Paper page
  12. Casado, 2013, Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors, Genome Biol., 14, R37, 10.1186/gb-2013-14-4-r37 · DOI · Paper page
  13. Chicz, 1992, Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size, Nature, 358, 764, 10.1038/358764a0 · DOI · Paper page
  14. Chikata, 2019, Identification of immunodominant HIV-1 epitopes presented by HLA-C*12:02, a protective allele, using an immunopeptidomics approach, J. Virol., 93
  15. Cobbold, 2013, MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia, Sci. Transl. Med., 5, 10.1126/scitranslmed.3006061 · DOI · Paper page
  16. Colaert, 2009, Improved visualization of protein consensus sequences by iceLogo, Nat. Methods, 6, 786, 10.1038/nmeth1109-786 · DOI · Paper page
  17. Cole, 2015, The ultimate mix and match: making sense of HLA alleles and peptide repertoires, Immunol. Cell Biol., 93, 515, 10.1038/icb.2015.40 · DOI
  18. Croft, 2019, Most viral peptides displayed by class I MHC on infected cells are immunogenic, Proc. Natl. Acad. Sci., 116, 3112, 10.1073/pnas.1815239116 · DOI
  19. Demmers, 2019, Pre-fractionation extends but also creates a Bias in the detectable HLA class iota ligandome, J. Proteome Res., 18, 1634, 10.1021/acs.jproteome.8b00821 · DOI · Paper page
  20. Depontieu, 2009, Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy, Proc. Natl. Acad. Sci. U.S.A., 106, 12073, 10.1073/pnas.0903852106 · DOI · Paper page
  21. Dudek, 2012, Constitutive and inflammatory immunopeptidome of pancreatic β-Cells, Diabetes, 61, 3018, 10.2337/db11-1333 · DOI
  22. Ebrahimi-Nik, 2019, Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection, JCI Insight, 5
  23. Escher, 2012, Using iRT, a normalized retention time for more targeted measurement of peptides, Proteomics, 12, 1111, 10.1002/pmic.201100463 · DOI · Paper page
  24. Falk, 1991, Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules, Nature, 351, 290, 10.1038/351290a0 · DOI · Paper page
  25. Faridi, 2018, In immunopeptidomics we need a sniper instead of a shotgun, Proteomics., 10.1002/pmic.201700464 · DOI · Paper page
  26. Faure, 2004, Inducible Hsp70 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes, Int. J. Cancer, 108, 863, 10.1002/ijc.11653 · doi:10.1002/ijc.11653
  27. Frese, 2013, Unambiguous phosphosite localization using electron-transfer/higher-energy collision dissociation (EThcD), J. Proteome Res., 12, 1520, 10.1021/pr301130k · DOI · Paper page
  28. Freudenmann, 2018, Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry, Immunology, 154, 331, 10.1111/imm.12936 · DOI · Paper page
  29. Garde, 2019, Improved peptide-MHC class II interaction prediction through integration of eluted ligand and peptide affinity data, Immunogenetics., 10.1007/s00251-019-01122-z · DOI · Paper page
  30. Gloger, 2016, Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes, Cancer Immunol. Immunother., 65, 1377, 10.1007/s00262-016-1897-3 · DOI · Paper page
  31. Hoof, 2009, NetMHCpan, a method for MHC class I binding prediction beyond humans, Immunogenetics, 61, 1, 10.1007/s00251-008-0341-z · DOI · Paper page
  32. Hornbeck, 2012, PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse, Nucleic Acids Res., 40, D261, 10.1093/nar/gkr1122 · DOI · Paper page
  33. Hulsen, 2008, BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams, BMC Genomics, 9, 488, 10.1186/1471-2164-9-488 · DOI · Paper page
  34. Hunt, 1992, Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry, Science, 255, 1261, 10.1126/science.1546328 · DOI · Paper page
  35. Illing, 2012, Immune self-reactivity triggered by drug-modified HLA-peptide repertoire, Nature, 486, 554, 10.1038/nature11147 · DOI · Paper page
  36. Jurtz, 2017, NetMHCpan-4.0: improved Peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data, J. Immunol., 199, 3360, 10.4049/jimmunol.1700893 · DOI · Paper page
  37. Kyte, 1982, A simple method for displaying the hydropathic character of a protein, J. Mol. Biol., 157, 105, 10.1016/0022-2836(82)90515-0 · DOI · Paper page
  38. Loffler, 2019, Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma, Genome Med., 11, 28, 10.1186/s13073-019-0636-8 · DOI · Paper page
  39. Mason, 1998, A very high level of crossreactivity is an essential feature of the T-cell receptor, Immunol. Today, 19, 395, 10.1016/S0167-5699(98)01299-7 · DOI · Paper page
  40. Mommen, 2014, Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD), Proc. Natl. Acad. Sci., 111, 4507, 10.1073/pnas.1321458111 · DOI · Paper page
  41. Narayan, 2019, Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin, PLoS One, 14, 10.1371/journal.pone.0219547 · DOI
  42. Naylor, 1998, Membrane preconcentration-capillary electrophoresis tandem mass spectrometry (mPC-CE-MS/MS) in the sequence analysis of biologically derived peptides, Talanta, 45, 603, 10.1016/S0039-9140(97)00186-0 · doi:10.1016/s0039-9140(97)00186-0
  43. Newey, 2019, Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment, J. Immunother. Cancer, 7, 309, 10.1186/s40425-019-0769-8 · DOI
  44. Olsen, 2017, TANTIGEN: a comprehensive database of tumor T cell antigens, Cancer Immunol. Immunother., 66, 731, 10.1007/s00262-017-1978-y · DOI
  45. Parham, 1981, Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28, Hum. Immunol., 3, 277, 10.1016/0198-8859(81)90065-3 · DOI · Paper page
  46. Parker, 1992, Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2, J. Immunol., 149, 3580, 10.4049/jimmunol.149.11.3580 · DOI · Paper page
  47. Partridge, 2018, Discrimination between human leukocyte antigen class I-Bound and Co-purified HIV-Derived peptides in immunopeptidomics workflows, Front. Immunol., 9
  48. Perez-Riverol, 2018, The PRIDE database and related tools and resources in 2019: improving support for quantification data, Nucleic Acids Res., 47, D442, 10.1093/nar/gky1106 · DOI · Paper page
  49. Purcell, 2007, More than one reason to rethink the use of peptides in vaccine design, Nat. Rev. Drug Discov., 6, 404, 10.1038/nrd2224 · DOI · Paper page
  50. Ramarathinam, 2018, Employing proteomics in the study of antigen presentation: an update, Expert Rev. Proteomics, 15, 637, 10.1080/14789450.2018.1509000 · DOI
  51. Ramarathinam, 2018, Identification of native and posttranslationally modified HLA-B*57:01-Restricted HIV envelope derived epitopes using immunoproteomics, PROTEOMICS, 18, 10.1002/pmic.201700253 · DOI
  52. Rammensee, 1995, Chemistry of peptides associated with MHC class I and class II molecules, Curr. Opin. Immunol., 7, 85, 10.1016/0952-7915(95)80033-6 · DOI · Paper page
  53. Sahay, 2017, Conserved HIV epitopes for an effective HIV vaccine, J. Clin. Cell. Immunol., 8
  54. Schuster, 2018, A tissue-based draft map of the murine MHC class I immunopeptidome, Sci. Data, 5, 10.1038/sdata.2018.157 · DOI
  55. Ternette, 2018, Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens, Proteomics, 18
  56. Tsuchiya, 1980, Establishment and characterization of a human acute monocytic leukemia cell line (THP-1), Int. J. Cancer, 26, 171, 10.1002/ijc.2910260208 · DOI · Paper page
  57. Woods, 2019, The diversity of the immunogenic components of the melanoma immunopeptidome, bioRxiv
  58. Zarling, 2006, Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy, Proc. Natl. Acad. Sci. U.S.A., 103, 14889, 10.1073/pnas.0604045103 · DOI · Paper page
  59. Zemmour, 1992, The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon, J. Immunol., 148, 1941, 10.4049/jimmunol.148.6.1941 · doi:10.4049/jimmunol.148.6.1941
  60. Zhang, 2012, PEAKS DB: de novo sequencing assisted database search for sensitive and accurate peptide identification, Mol. Cell Proteomics, 11, 10.1074/mcp.M111.010587 · DOI · Paper page

Cited by

See all 26

Metadata

Authors
Pandey, K., Mifsud, N. A., Lim Kam Sian, T. C. C., Ayala, R., Ternette, N., Ramarathinam, S. H., & Purcell, A. W.
Venue
Molecular Immunology
Publisher
Elsevier BV
Published
2020-07
Volume
123
Pages
7-17
ISSN
0161-5890
Cited by
26
References
4
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Cancer Research UK (A21998, 1137739)
  • National Health and Medical Research Council (1122099, 1165490)
  • Australian Research Council

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.